Loading...
Publication
Caracterização fenotípica de isolados de Shigella spp. entre 2015 e 2017
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 626.37 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Em Portugal, a shigelose é uma gastroenterite pouco frequente. Com este
estudo pretendeu-se descrever os serotipos de Shigella spp. identificados
no Laboratório Nacional de Referência de Infeções Gastrintestinais do
Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA) entre 2015 e 2017.
Foram analisadas estirpes isoladas de 53 doentes, que foram enviadas
a nível nacional ao INSA para serotipagem. A suscetibilidade aos antimicrobianos
foi realizada segundo as recomendações do European Committee on
Antimicrobial Susceptibility Testing (EUCAST). Os serotipos mais frequentemente
encontrados foram Sh. sonnei (n=37; 69,8%), Sh. flexneri 2 (n=7;
13,2%), Sh. flexneri 3 (n=3; 5,7%). Foi observada uma elevada percentagem
de resistência à tetraciclina (47/53; 88,7%). Em 2017, todas as estirpes
apresentaram resistência à ampicilina e a percentagem de estirpes com
resistência à ciprofloxacina aumentou consideravelmente, de 5,0% em 2015
para 62,5% em 2017. Cerca de 50% das estirpes apresentaram resistência
à azitromicina durante o período em análise. Foram detetados 4 casos de
Shigella spp. multirresistentes em homens que fazem sexo com homens
(HSH). O aumento de resistências aos antibióticos observados nestes dois
anos alerta para a importância de uma vigilância ativa das mesmas e impõe
uma articulação efetiva entre os diversos serviços de saúde envolvidos.
Shigella is a rare cause of gastrointestinal disease in Portugal. This study describes Shigella serotypes identified in National Reference Laboratory for Gastrointestinal Diseases of National Institute of Health Doutor Ricardo Jorge (INSA) from 2015 to 2017. We analysed the strains isolated from fifty three patients. Antimicrobial susceptibility testing wasperformed according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). The most frequent serotypes were Sh. sonnei (n=37; 69.8%), Sh. flexneri 2 (n=7; 13.2%), Sh. flexneri 3 (n=3; 5.7%). We observed a high frequency of resistance to tetracycline (47/53; 88.7%). In 2017, all strains presented resistance to ampicillin and the percentage of strains resistant to ciprofloxacin increased from 5.0% in 2015 to 62.5% in 2017. About 50% of the strains were resistant to azithromycin. We detected four cases of multiresistant Shigella spp. in men who have sex with men (MSM). The increase of resistant strains observed in these two years alerts to the importance of an active vigilance and to the need of an effective articulation of the several health services involved.
Shigella is a rare cause of gastrointestinal disease in Portugal. This study describes Shigella serotypes identified in National Reference Laboratory for Gastrointestinal Diseases of National Institute of Health Doutor Ricardo Jorge (INSA) from 2015 to 2017. We analysed the strains isolated from fifty three patients. Antimicrobial susceptibility testing wasperformed according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). The most frequent serotypes were Sh. sonnei (n=37; 69.8%), Sh. flexneri 2 (n=7; 13.2%), Sh. flexneri 3 (n=3; 5.7%). We observed a high frequency of resistance to tetracycline (47/53; 88.7%). In 2017, all strains presented resistance to ampicillin and the percentage of strains resistant to ciprofloxacin increased from 5.0% in 2015 to 62.5% in 2017. About 50% of the strains were resistant to azithromycin. We detected four cases of multiresistant Shigella spp. in men who have sex with men (MSM). The increase of resistant strains observed in these two years alerts to the importance of an active vigilance and to the need of an effective articulation of the several health services involved.
Description
Keywords
Shigella spp. Shigelose Infecções Gastrintestinais Saúde Pública
Pedagogical Context
Citation
Boletim Epidemiológico Observações. 2018 janeiro-abril;7(21):21-23
Publisher
Instituto Nacional de Saúde Doutor Ricardo Jorge, IP